A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial

References

• Kuwabara S, Shibuya K, Misawa S. Fasciculations, axonal hyperexcitability, and motoneuronal death in amyotrophic lateral sclerosis. Clin Neurophysiol. 2014;125:872–3.
   PubMed Web of Science ®Google Scholar
• Layzer RB. The origin of muscle fasciculations and cramps. Muscle Nerve. 1994;17:1243–9.
   PubMed Web of Science ®Google Scholar
• Kanai K, Kuwabara S, Misawa S, Tamura N, Ogawara K, Nakata M, et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain. 2006;129:953–62.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Misawa S, Arai K, Nakata M, Kanai K, Yoshiyama Y, et al. Markedly reduced axonal potassium channel expression in human sporadic amyotrophic lateral sclerosis: an immunohistochemical study. Exp Neurol. 2011;232:149–53.
   PubMed Web of Science ®Google Scholar
• Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol. 2006;117:1458–66.
   PubMed Web of Science ®Google Scholar
• Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Sonoo M, Komori T, Shimizu T, Hirashima F, Inaba A, et al. Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent, and specificity. Muscle Nerve. 2008;37:426–30.
   PubMed Web of Science ®Google Scholar
• Bae JS, Sawai S, Misawa S, Kanai K, Isose S, Kuwabara S. Differences in excitability properties of FDI and ADM motor axons. Muscle Nerve. 2009;39:350–4.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Misawa S, Nasu S, Sekiguchi Y, Mitsuma S, Beppu M, et al. Split hand syndrome in amyotrophic lateral sclerosis: different excitability changes in the thenar and hypothenar motor axons. J Neurol Neurosurg Psychiatry. 2013;84:969–72.
   PubMed Web of Science ®Google Scholar
• Kanai K, Shibuya K, Sato Y, Misawa S, Nasu S, Sekiguchi Y, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83:734–8.
   PubMed Web of Science ®Google Scholar
• Kuo JJ, Siddique T, Fu R, Heckman CJ. Increased persistent Na(+) current and its effect on excitability in motor neurons cultured from mutant SOD1 mice. J Physiol. 2005;563:843–54.
   PubMed Web of Science ®Google Scholar
• Pieri M, Carunchio I, Curcio L, Mercuri NB, Zona C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp Neurol. 2009;215:368–79.
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497–503.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS progression. J Neurol Sci. 2008;275:69–73.
   PubMed Web of Science ®Google Scholar
• Medical Research Council. Aids to examination of the peripheral nervous system. Vol. 1. London: Her Majesty's Stationary Office., 1976.
   Google Scholar
• Vucic S, Kiernan MC. Pathophysiologic insights into motor axonal function in Kennedy disease. Neurology. 2007; 69:1828–35.
   PubMed Web of Science ®Google Scholar
• Kasarskis EJ, Dempsey-Hall L, Thompson MM, Luu LC, Mendiondo M, Kryscio R. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:50–4.
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:456–60.
   PubMed Web of Science ®Google Scholar
• Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481–8.
   PubMed Web of Science ®Google Scholar
• Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L, et al. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler. 2009;10:410–5.
   PubMed Web of Science ®Google Scholar
• Cheah BC, Lin CS, Park SB, Vucic S, Krishnan AV, Kiernan MC. Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol. 2012;123:2460–7.
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Misawa S, Tamura N, Kanai K, Hiraga A, Ogawara K, et al. The effects of mexiletine on excitability properties of human median motor axons. Clin Neurophysiol. 2005;116:284–9.
   PubMed Web of Science ®Google Scholar
• Dong H, Xu L, Wu L, Wang X, Duan W, Li H, et al. Curcumin abolishes mutant TDP-43 induced excitability in a motor neuron-like cellular model of ALS. Neuroscience. 2014;272:141–53.
   PubMed Web of Science ®Google Scholar
• Rojas F, Cortes N, Abarzua S, Dyrda A, van Zundert B. Astrocytes expressing mutant SOD1 and TDP43 trigger motor neuron death that is mediated via sodium channels and nitroxidative stress. Front Cell Neurosci. 2014;8:24.
   PubMed Web of Science ®Google Scholar
• Piepers S, Veldink JH, de Jong SW, van der Tweel I, van der Pol WL, Uijtendaal EV, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol. 2009;66:227–34.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456–64.
   PubMed Web of Science ®Google Scholar
• Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17:1199–942.
   Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–7.
   PubMed Web of Science ®Google Scholar
• Manolis AS, Deering TF, Cameron J, Estes NA 3rd. Mexiletine: pharmacology and therapeutic use. Clin Cardiol. 1990;13:349–59.
   PubMed Web of Science ®Google Scholar